Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT06434519Completed
Randomised, open-label trial of metronidazole in rosacea (4 arms), sponsored by Duke University. Primary endpoint: Metronidazole penetrance through the stratum corneum (SC) at 4 hours. Started Sep 2024; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT06434519.